William Blair Issues Positive Outlook for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Research analysts at William Blair raised their Q1 2025 EPS estimates for Elanco Animal Health in a note issued to investors on Tuesday, February 25th. William Blair analyst B. Vazquez now forecasts that the company will post earnings of $0.32 per share for the quarter, up from their prior forecast of $0.30. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the company posted $0.08 EPS. The business’s revenue for the quarter was down 1.4% on a year-over-year basis.

Several other research firms have also issued reports on ELAN. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday. Finally, Stifel Nicolaus lowered their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.83.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $11.19 on Friday. Elanco Animal Health has a 52-week low of $10.20 and a 52-week high of $18.80. The firm has a fifty day moving average of $11.71 and a 200-day moving average of $13.03. The firm has a market capitalization of $5.53 billion, a P/E ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Hedge Funds Weigh In On Elanco Animal Health

Several large investors have recently bought and sold shares of ELAN. DDD Partners LLC bought a new position in shares of Elanco Animal Health during the 4th quarter valued at about $5,974,000. Geode Capital Management LLC boosted its position in shares of Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after purchasing an additional 65,303 shares in the last quarter. Atom Investors LP boosted its position in shares of Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock valued at $5,081,000 after purchasing an additional 261,559 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after purchasing an additional 209,734 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Elanco Animal Health by 19.2% in the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after buying an additional 646,522 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.